Clinical Trial Update: Serum CA9 Level as Biological Marker of the Treatment Response in Metastatic Renal Cell Cancer

View source ↗

Summary

A terminated clinical trial evaluating serum CA9 as a biomarker of treatment response in metastatic renal cell carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma Metastatic

Snippet

Sponsor: Centre Hospitalier Universitaire de Saint Etienne | Conditions: Metastatic Kidney Cancer, Metastatic Renal Cell Carcinoma | Status: TERMINATED